Ultime notizie per Oportun Financial (NASDAQ:OPRT) Azioni

Oportun Financial

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

WIIM

SCCO

Shares of copper stocks are trading higher after President Trump said he believes copper tariffs will be 50%.

Oppenheimer analyst Chad Larkin maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Outperform and raises the price target from $17 to $20.

News

Price Target

Analyst Ratings

LYFT

Oppenheimer Maintains Outperform on Lyft, Raises Price Target to $20

Oppenheimer analyst Ian Zaffino maintains Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Outperform and raises the price target from $47 to $55.

Oppenheimer Maintains Outperform on Kyndryl Hldgs, Raises Price Target to $55

Oppenheimer analyst Owen Lau maintains Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Outperform and raises the price target from $2293 to $2300.

FICO

Oppenheimer Maintains Outperform on Fair Isaac, Raises Price Target to $2300

<a href="https://www.youtube.com/live/vL6PaBTA4I8">https://www.youtube.com/live/vL6PaBTA4I8</a>

Politics

General

President Trump Says We Are Thinking Of Taking Over Governance Of Washington D.C.; Says "Not Getting Involved" In NYC Mayoral Race

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock may be down 20% year-to-date in 2025, but that's not stopping analysts and investors, including Ark Invest to bet on the company's future success thanks to robotaxis, less expensive electric vehicles and <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">other future catalysts.</a>
Here&#8217;s a look at Ark Invest CEO&nbsp;Cathie Wood&#8217;s&nbsp;future price targets for Tesla and how investors could still benefit if she is right about the EV leader again.
Following Wood Into Tesla:&nbsp;Wood&nbsp;<a href="https://www.benzinga.com/news/21/01/19082834/with-tesla-over-800-arks-catherine-wood-proves-doubters-wrong-on-huge-bullish-call-from-2018" target="_blank" rel="noreferrer noopener">famously called a bullish&nbsp;</a>price target of $4,000 on Tesla in 2018 that came true (split-adjusted) years later. While many were skeptical of Wood&#8217;s high price target at the time, her conviction paid off and helped cement her status in the financial community.
Wood&nbsp;announced a&nbsp;$2,600 price target for Tesla in<a href="https://www.benzinga.com/etfs/specialty-etfs/24/06/39294523/cathie-wood-ark-invest-set-new-2-600-price-target-for-tesla-every-car-becomes-an-ai-powered-c" target="_blank" rel="noreferrer noopener">&nbsp;June 2024</a>, raising the bar from a previous price target of $2,000 for the electric vehicle stock.
Ark Invest has a price target of $2,600 for Tesla by the year 2029, with a bear case price target of $2,000 and a bull case of $3,100.
With Tesla shares trading at $301.98 today, an investor could purchase 3.31 shares with a $1,000 investment
Here's a look at how much the $1,000 could be worth in 2029 if Wood's various price targets come true:
<ul class="wp-block-list">
<li>$2,000 Bear Case: $6,602, +560.2%</li>
<li>$2,600 Base Case: $8,606, +760.6%</li>
<li>$3,100 Bull Case: $10,261, +926.1%</li>
</ul>
Each of the price targets from Wood would gain 560% or more, representing huge returns over the next five years.
Keep in mind that the average return of the S&amp;P 500 Index is around 10.5% annually since the fund's 1957 inception. The price target from Wood would mark a sizable outperformance to historical stock index returns.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important:&nbsp;Wood reiterated her $2,600 price target for Tesla <a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">earlier this year</a> in several interviews. The fund manager said robotaxis represents a software-as-a-service-like business model that will provide high operating margins for Tesla.
The new price target is based on several factors, with the majority of the price target coming from Tesla's robotaxi ambitions.
"ARK estimates that nearly 90% of Tesla's enterprise value and earnings will be attributed to the robotaxi business in 2029," the open-source model reads.
Aside from the new price targets in the thousands of dollars, Ark also lists a price target of $350 for Tesla if it eliminates the robotaxi network from the model, stressing the importance of this future catalyst.
The new price target forecast model breaks down Tesla's 2029 revenue as 63% from robotaxis and 26% from electric vehicles, with the rest coming from items such as insurance and energy storage.
Ark Invest estimates that Tesla could have revenue of $1.2 trillion in 2029 and EBITDA of $440 billion. The prediction assumes that Tesla will sell 5.8 million electric vehicles in 2029.
"Tesla plans to unveil its dedicated robotaxi vehicle in August 2024. While Tesla could transform its current fleet into robotaxis, we believe a custom-built CyberCab reflects increased confidence that its autonomy software will allow Tesla to scale the robotaxi business."
The new Ark Invest price target does not include any impact from the Tesla Semi, Tesla Supercharging network, FSD licensing or AI-As-A-Service. The price model includes minimal results from the Optimus bot.
"(Tesla's) business model should transform from one-off vehicle sales to a recurring revenue base as every car becomes an AI-powered cash flow generation machine."
Wood's new price targets would take Tesla to a market capitalization of between $7 trillion and $10.9 trillion and the title of the world's most valuable company.
Tesla CEO&nbsp;Elon Musk&nbsp;recently highlighted&nbsp;<a href="https://www.benzinga.com/news/24/06/39324085/elon-musk-thanks-shareholders-says-tesla-starting-a-new-book-could-hit-30-trillion-valuation-hot-d-i" target="_blank" rel="noreferrer noopener">the potential value&nbsp;</a>of the robotaxi business and Optimus bot as the catalysts that could make Tesla the most valuable company in the world, worth north of $30 trillion.
Many laughed at Wood when she made her bullish $4,000 price prediction. Years later, the stock was north of that level on a split-adjusted value. Wood continues to bet heavily on Tesla with the Ark Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>), Ark Next Generation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) and Ark Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) <a href="https://www.ark-funds.com/" target="_blank" rel="noreferrer noopener">counting </a>
Tesla is the top holding in ARKK and ARKQ at 9.14% and 9.94% of assets, respectively. In ARKW, Tesla is the fourth-largest holding at 6.18% of assets at the time of writing.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
This article was previously published by Benzinga and has been updated.

Long Ideas

Education

Trading Ideas

ARKK

ARKQ

ARKW

TSLA

Here's How Much $1,000 Invested In Tesla Stock Today Will Be Worth If Cathie Wood's Price Prediction Comes True In 2029

Oppenheimer analyst Bryan Blair maintains SPX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) with a Outperform and raises the price target from $170 to $197.

SPXC

Oppenheimer Maintains Outperform on SPX Technologies, Raises Price Target to $197

Citigroup analyst Patrick Cunningham maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Buy and lowers the price target from $26 to $25.

Citigroup Maintains Buy on Olin, Lowers Price Target to $25

CRCL

CRCL stock has given up its prior loss. Circle Internet Group shares were trading lower after Mizuho initiated coverage on the stock with an Underperform rating and announced a price target of $85.

President Trump Says Will Take Two Years To Build It; Will Have Contract Probably Over Next Couple Of Months

Citigroup analyst Patrick Cunningham maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Neutral and lowers the price target from $30 to $28.

Citigroup Maintains Neutral on Dow, Lowers Price Target to $28

Roth Capital analyst Matt Koranda reiterates Kits Eyecare (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KITS#TSX">KITS</a>) with a Buy and maintains C$22 price target.

Reiteration

TSX:KITS

Roth Capital Reiterates Buy on Kits Eyecare, Maintains C$22 Price Target

President Trump Says Want To Have One Company For Air Traffic Control Modernization; Raytheon, IBM Will Bid

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $325 to $415.

CVNA

Citigroup Maintains Buy on Carvana, Raises Price Target to $415

In a significant legal challenge that could reshape the future of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">public health policy</a> in the United States, a powerful alliance of leading medical and public health organizations, including the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and the American Public Health Association (APHA), filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Secretary Kennedy has launched an &#8220;assault on science, public health, and evidence-based medicine&#8221; through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children and pregnant individuals.
This unprecedented <a target="_blank" href="https://www.aap.org/en/news-room/news-releases/aap/2025/leading-medical-professional-societies-patients-sue-hhs-robert-f-kennedy-jr-for-unlawful-unilateral-vaccine-changes/?_gl=1&#x2A;12sk5li&#x2A;_ga&#x2A;NTIxOTQ2NTgyLjE3NTE5NzQ2MjA.&#x2A;_ga_FD9D3XZVQQ&#x2A;czE3NTE5NzQ2MTkkbzEkZzEkdDE3NTE5NzQ2MjYkajUzJGwwJGgw" rel="noreferrer noopener">legal action</a> seeks to halt what the coalition describes as an &#8220;existential threat to vaccination in America,&#8221; arguing that Kennedy&#8217;s directives, including the controversial dismissal of expert advisors from the CDC&#8217;s immunization committee, are endangering the nation&#8217;s long-standing, science-based vaccine infrastructure and, critically, the health of its most vulnerable populations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/07/46256464/lawmakers-investigate-whether-pfizer-delayed-covid-19-vaccine-results-for-political-reasons" rel="noreferrer noopener">Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons</a>
<h2 class="wp-block-heading">Lawsuit Details And Allegations</h2>
The comprehensive lawsuit, filed in the U.S. District Court for the District of Massachusetts, names the U.S. Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. as defendants. The plaintiffs, which also include the Infectious Diseases Society of America (IDSA), the Massachusetts Public Health Alliance (MPHA), the Society for Maternal-Fetal Medicine (SMFM), and a pregnant physician, assert that Kennedy acted &#8220;arbitrarily and capriciously&#8221; by altering COVID-19 vaccine recommendations for children and pregnant people without scientific basis.
This follows Secretary Kennedy&#8217;s public statement in May, where he <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">expressed pleasure at the removal</a> of the COVID-19 vaccine for healthy children and pregnant women from CDC recommended immunization schedules.
A critical aspect of the lawsuit&#8217;s complaint is Secretary Kennedy&#8217;s alleged unjust dismissal of 17 members of the Centers for Disease Control and Prevention&#8217;s (CDC) Advisory Committee on Immunization Practices (ACIP). These experts were reportedly replaced with individuals known for espousing anti-vaccine viewpoints.
Dr. Susan J. Kressly, President of the AAP, underscored the gravity of these actions, stating, &#8220;This wasn&#8217;t just sidelining science. It&#8217;s an attack on the very foundation of how we protect families and children&#8217;s health. And the consequences could be dangerous.&#8221;
The lawsuit further details a pattern of interference, including blocked CDC communications, delayed or canceled meetings of CDC and Food and Drug Administration (FDA) vaccine advisers, and the announcement of studies to investigate non-existent links between vaccines and autism.
<h2 class="wp-block-heading">Seeking Injunctions And Protecting Public Health</h2>
The plaintiffs are seeking both preliminary and permanent injunctions to reverse Secretary Kennedy&#8217;s rescissions of COVID-19 vaccine recommendations. They also request a declaratory judgment to legally pronounce these changes as unlawful. Richard H. Hughes IV, lead counsel for the plaintiffs and partner at Epstein Becker Green, voiced grave concerns, asserting, &#8220;This administration is an existential threat to vaccination in America, and those in charge are only just getting started. If left unchecked, Secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation&#8217;s children.&#8221;
The lawsuit alleges that the Directive is but one example of the Secretary&#8217;s agenda to dismantle the long-standing, Congressionally-authorized, science- and evidence-based vaccine infrastructure that has prevented the deaths of untold millions of Americans. The filing highlights that the Secretary&#8217;s dismantling of the vaccine infrastructure must end, and halting this effort begins with vacating the Directive.
<h2 class="wp-block-heading">FDA&#8217;s Internal Disagreements And Historical Legal Actions</h2>
Per a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration&#8217;s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.
While distinct from the HHS lawsuit, this report underscores a broader climate of scrutiny and debate surrounding vaccine policy.
The AAP has a history of pursuing legal action against the federal government, regardless of political affiliation. Past instances include a 1983 lawsuit against HHS regarding life-sustaining treatment for infants and separate lawsuits against the FDA in 2016 and 2018 concerning graphic warnings on cigarettes and e-cigarette regulation, respectively.
Price Action: MRNA stock is trading higher by 11% to $33.18, and NVAX stock is up 6.61% at $7.05 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46301475/coreweaves-9-billion-bet-turns-crypto-miner-into-ai-powerhouse" target="_blank" rel="noreferrer noopener">CoreWeave&#8217;s $9 Billion Bet Turns Crypto Miner Into AI Powerhouse</a></li>
</ul>
Photo by lev radin via Shutterstock

Biotech

Government

Health Care

Legal

MRNA

NVAX

Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks

Citigroup analyst Christopher Allen maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Neutral and raises the price target from $230 to $245.

CBOE

Citigroup Maintains Neutral on Cboe Global Markets, Raises Price Target to $245

Roth Capital analyst Darren Aftahi downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Neutral and maintains the price target from $20 to $20.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

Roth Capital Downgrades Core Scientific to Neutral, Maintains Price Target to $20

Citigroup analyst Alexander Hacking maintains Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Neutral and raises the price target from $44 to $48.

Citigroup Maintains Neutral on Freeport-McMoRan, Raises Price Target to $48

<a href="https://www.bloomberg.com/news/articles/2025-07-08/waymo-starts-offering-teen-accounts-first-in-metro-phoenix-more-cities-later" title="https://www.bloomberg.com/news/articles/2025-07-08/waymo-starts-offering-teen-accounts-first-in-metro-phoenix-more-cities-later">https://www.bloomberg.com/news/articles/2025-07-08/waymo-starts-offering-teen-accounts-first-in-metro-phoenix-more-cities-later</a>

GOOG

GOOGL

'Waymo Begins Offering Teen Accounts, Starting in Metro Phoenix' - Bloomberg News

Roth Capital analyst Rohit Kulkarni maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $620 to $740.

Roth Capital Maintains Buy on Meta Platforms, Raises Price Target to $740

Press Releases

Findell Capital Provides Facts in Response to Oportun's Misleading Narrative

Findell Capital Releases Presentation on Oportun Financial

Findell Capital Reiterates Commitment to Reaching a Good Faith Settlement at Oportun Financial

Oportun Releases Investor Presentation Highlighting Strategic Progress

Management

Oportun Issues Letter to Stockholders Detailing CEO Raul Vazquez's Record of Proven Leadership

Findell Capital Issues Rebuttal Presentation on Oportun Financial and Notes Support of Oportun Founder and Former CEO James Gutierrez

Findell Capital Reiterates Desire for Compromise at Oportun Financial and Issues Statement on Behalf of Scott Parker

Oportun Responds to Comments by Findell Capital

Findell Reports ISS Recommends Oportun Stockholders Vote FOR Findell Nominee Warren Wilcox and WITHHOLD on Long-Tenured CEO Raul Vazquez at Annual Meeting

Comments

Oportun Financial

Notizie

Ultime notizie per Oportun Financial (NASDAQ:OPRT) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO